Revolution Medicines’ new pancreatic cancer treatment has opened with sales far above analyst expectations in its first weeks on the market.
Early revenue figures suggest the drug is on pace for one of the strongest launch trajectories seen in oncology, according to market watchers.
The drug targets a form of pancreatic cancer that has long resisted most standard therapies, giving it a relatively clear path in the clinic.
Demand has come from treatment centers quick to adopt the therapy, with prescribing concentrated among specialists familiar with the drug’s profile.
Pancreatic cancer remains one of the deadliest tumor types, and new options have been scarce, which helps explain the fast uptake.
Analysts caution that early sales can overstate long-term performance, and insurer coverage decisions will shape the coming quarters.
Revolution Medicines has not yet released full launch guidance, leaving investors to weigh the initial surge against supply and pricing factors.
